Lakeside Holding (LSH) investor relations material

Executive summary

• Revenue for the quarter ended September 30, 2025, was $6.1 million, up 49.5% year-over-year, driven by growth in cross-border airfreight and the launch of pharmaceutical distribution in China.

• Gross profit increased 112.2% to $1.1 million, with overall gross margin rising to 18.2% from 12.8% a year ago.

• Net loss was $1.4 million, compared to $1.3 million in the prior year, reflecting higher operating and interest expenses.

Financial highlights

• Cross-border airfreight revenue rose 48.2% to $3.3 million, offsetting a 21.9% decline in ocean freight revenue.

• Pharmaceutical distribution contributed $1.3 million in revenue and a 40.9% gross margin in its first full quarter.

• Operating expenses increased 28.7% to $2.4 million, mainly due to higher G&A and selling expenses from business expansion.

• Interest expense surged 598.8% to $196,441 due to increased borrowings and convertible debt.

• Cash balance at quarter-end was $4.5 million, with a current ratio of 1.5 and working capital of $5.2 million.

Outlook and guidance

• Management plans to continue expanding the customer base, especially in the pharmaceutical segment, while focusing on cost control and service quality.

• The company expects increased capital expenditures and ongoing investments in supply chain capabilities and marketing.

• Uncertainties remain due to U.S.-China trade policy, regulatory changes, and macroeconomic conditions.